論文・技術情報追加のお知らせ

1. Bridging pharmacovigilance and genetic insight: investigating drugs and indications for breast cancer risk in women with autoimmune diseases.

自己免疫疾患女性で乳がん関連薬剤と遺伝的要因を特定

対象DB：FAERS

2. Safety profile of metformin in adolescents with type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System.

思春期T2Dでメトホルミンに多様な副作用シグナル

対象DB：FAERS,KAERS

3. Valproate sodium-associated acute pancreatitis: a case report and systematic analysis of antiepileptic drug adverse events in FAERS.

VPA含む多くの抗てんかん薬で膵炎リスクを確認

対象DB：FAERS

4. Reporting patterns of multiple sclerosis with immune checkpoint inhibitors: analysis of the FDA Adverse Event Reporting System.

ICIでMSは増えず。他の神経免疫疾患は高リスク

対象DB：FAERS

5. A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis.

PCSK9阻害薬全体で過敏症の有意な増加なし

対象DB：CVAR,FAERS

6. Cardiotoxicity of different 5-HT3 receptor antagonists analyzed using the FAERS database and pharmacokinetic study.

5-HT3拮抗薬で心毒性差、特にオンダンが高リスク

対象DB：FAERS

7. Adverse events associated with single-ingredient folic acid in pregnancy: A descriptive analysis of the United States Food and Drug Administration Adverse Event Reporting System (2004-2025).

妊娠中の葉酸補給で稀な重大有害事象報告

対象DB：FAERS

8. Tiopronin safety in cystinuria: first real-world pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS): an EAU YAU and Endourology sections review.

チオプロニンで小児中心に新規有害事象が判明

対象DB：FAERS

9. A disproportionality analysis of nifedipine in the overall population and in pregnant women using the FDA Adverse Event Reporting System (FAERS) database.

妊娠中ニフェジピンで肺水腫等の新規有害事象を確認

対象DB：FAERS

10. Adverse Event Profiles of Acetaminophen and Ibuprofen in Infants: A Food and Drug Administration Adverse Event Reporting System Database Retrospective Cohort Study.

乳児で解熱薬の安全性差が明確に判明

対象DB：FAERS

11. Association between oral JAK-1 inhibitors and infection risks in atopic dermatitis: a retrospective analysis of the FAERS database.

JAK1阻害薬で帯状疱疹など感染症リスク確認

対象DB：FAERS

12. Insights from pharmacovigilance databases, clinical cohorts and preclinical models into VEGF(R) inhibitor-induced arthritis in cancer.

VEGFR阻害薬で関節炎が増加し機序も解析

対象DB：FAERS,VigiBase

13. Identifying high-risk drugs and demographic patterns in drug-induced liver injury from FAERS and CVARD analyses.

DILI関連薬を大規模解析し高リスク薬を特定

対象DB：CVAR,FAERS

14. A pharmacovigilance study of daptomycin use in infants under 1 year old based on the FDA adverse event reporting system.

乳児でダプトマイシンに肝障害等の新規シグナル

対象DB：FAERS

15. Disproportionality Analysis of Nemolizumab in Patients with Atopic Dermatitis: A Real-World Pharmacovigilance Study.

ネモリズマブで新たな有害事象も報告

対象DB：FAERS

16. Drug-induced liver injury: a real-world pharmacovigilance study using the FDA adverse event reporting system database 2004-2024.

抗がん剤でDILI高リスクが多数確認された

対象DB：FAERS

17. Comparative safety evaluation of pentavalent (DTaP-IPV-Hib) and hexavalent (DTaP-IPV-Hib-HepB) vaccines in infants: a real-world analysis based on VAERS.

六価ワクチンは低月齢でAEFIが多く慎重観察が必要

対象DB：FAERS,VAERS

18. The real-world safety of lacosamide and perampanel in children: a disproportionality analysis of the FDA Adverse Event Reporting System.

小児でラコサミドは心疾患、ペランパネルは精神症状に注意

対象DB：FAERS

19. Real-world safety of Symdeko: insights from the food and drug administration adverse event reporting system.

Symdekoで新たな精神症状・腎結石のシグナルを確認

対象DB：FAERS

20. A Real-World Disproportionality Analysis of Avacopan in Anti-Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System.

アバコパンで感染・肝障害等の新規有害事象シグナルを確認

対象DB：FAERS

21. Hepatobiliary Adverse Events Linked to Immune Checkpoint Inhibitors: A Real-World Pharmacovigilance Analysis Using FAERS Data.

PD-1/PD-L1で肝障害パターンが異なり薬剤別監視が重要

対象DB：FAERS

22. Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system.

クラドリビンで多様な有害事象報告、早期発現に注意

対象DB：FAERS

23. Disproportionality Analysis of Urinary Stone Formation with Carbonic Anhydrase Inhibitors: A VigiBase Analysis.

CAIで結石リスク上昇、特に若年・高用量で注意

対象DB：VigiBase

24. CFTR during pregnancy and adverse drug reactions: A pharmacovigilance disproportionality analysis in VigiBase.

CFTR調節薬で流産・子癇前症の報告増も因果不明

対象DB：VigiBase

25. [Medical Care Cost for Older Adults in Japan:From the Cost Analysis of Transcatheter Aortic Valve Replacement and Surgical Aortic Valve Replacement].

高齢者TAVRは入院費高いが自己負担少ない

対象DB：DPC

26. Cost and outcome comparison between intradiscal condoliase injection and surgical treatment for lumbar disc herniation based on real-world data analysis.

低侵襲ICITは安価で感染少ないが再手術率高い

対象DB：DPC

27. Capturing surgical site infection after hip fracture surgery : insights from linked routine data.

股骨骨折術後SSIは過少把握され、診断遅延も多い

対象DB：CPRD

28. Tooth Extraction, Dental Visits, and Glucose Levels: a Retrospective Study.

定期歯科受診と抜歯は血糖悪化を抑制

対象DB：DeSC